Condition: Primary Progressive Multiple Sclerosis · Secondary Progressive Multiple Sclerosis (SPMS) · Multiple Sclerosis · Sponsor: Tr1X, Inc.
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS? * At what dose does TRX319 work the best to treat participants with primary and or secondary progressive MS? * Is pre-conditioning (with Bendamustine) needed to allow TRX319 to better treat participants with primary and/or secondary progressive MS? Participants will be asked to be on study for up 1 year and may receive up to 3 total administrations of TRX319. While on study, participants will have blood tests and other assessments (MRI scans and lumbar punctures) done to understand the safety of TRX319 and how it may benefit their multiple sclerosis.
This description comes directly from the study's public registry record.
Tr1X Clinical Trials · 858-283-7879 · Tr1xClinicalTrials@Tr1x.bio
Study Team · Tr1xClinicalTrials@Tr1x.bio
Always discuss trial participation with your own doctor first.
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| Washington University, St. Louis | St Louis, Missouri, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07477639